SCHEMBL16888449

SCHEMBL16888449

CC1CC(C)(C)Cc2nc3sc(C(N)=O)c(N)c3c(-c3ccco3)c21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EEF2K O00418 13/20 1.00
MAPT P10636 2/20 0.59
HTT P42858 2/20 0.59
USP2 O75604 1/20 0.59
PTK2B Q14289 1/20 0.59
HSD17B10 Q99714 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
IKBKB O14920 1/20 0.52
LIMK1 P53667 1/20 0.48
ALDH1A1 P00352 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
KMT2A Q03164 1/20 0.46
KDM4E B2RXH2 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18186069 0.93 EEF2K (0.86) EEF2KMAPTHTTUSP2PTK2B
SCHEMBL16888395 0.85 EEF2K (1.00) EEF2KMAPTALDH1A1MEN1KMT2A
SCHEMBL16888388 0.81 EEF2K (1.00) EEF2KMAPTHTTUSP2PTK2B
SCHEMBL16888441 0.80 EEF2K (1.00) EEF2KMAPTHTTUSP2PTK2B
SCHEMBL16888393 0.79 EEF2K (1.00) EEF2KHTTALDH1A1LMNAKDM4E
SCHEMBL18186052 0.78 EEF2K (0.87) EEF2KMAPTALDH1A1MEN1KMT2A
SCHEMBL430534 0.75 MAPT (1.00) EEF2KMAPTHTTUSP2PTK2B
SCHEMBL429326 0.75 MAPT (1.00) EEF2KMAPTHTTUSP2PTK2B
SCHEMBL18186056 0.74 EEF2K (0.86) EEF2KMAPTHTTUSP2PTK2B
SCHEMBL18196097 0.74 EEF2K (1.00) EEF2KMAPTHTTUSP2PTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160318948-A1 Compounds Inhibiting Eukaryotic Elongation Factor 2 Kinase Activity LONGEVICA PHARMACEUTICALS INC (US) 2016-11-03 US disclosed
US-20160318948-A1 Compounds Inhibiting Eukaryotic Elongation Factor 2 Kinase Activity LONGEVICA PHARMACEUTICALS INC (US) 2016-11-03 US disclosed
WO-2015102752-A1 COMPOUNDS INHIBITING EUKARYOTIC ELONGATION FACTOR 2 KINASE ACTIVITY LONGEVICA PHARMACEUTICALS, INC. (US) 2015-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318948-A1 Compounds Inhibiting Eukaryotic Elongation Factor 2 Kinase Activity EEF2K, EIF2AK1, EIF4EBP1 EEF2K 1/4885MAPT 1525/4885HTT 1600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.